PRESS RELEASE: MHRA Award Accreditation for MAC's Phase 1 Site
October 17, 2016
MAC Neuroscience Centre of excellence, the early phase division of MAC Clinical Research, has been awarded Accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA) MANCHESTER, ENGLAND – October 17, 2016 – MAC Clinical Research (MAC) today announced it has been awarded MHRA accreditation for Phase 1 clinical trials located at its Citylabs facility within the Manchester Royal Infirmary Campus (MRI). With a strong team, MAC will continue to conduct a full range of phase 1 clinical trials with a focus on early phase patient studies.
MAC, with its well established UK network of later phase clinics, has a long history and successful track record in recruiting various patient groups into Clinical Trials. The new Early Phase Unit (EPU) is ideally placed for First-in-Human and First-in-Patient trials as well as the increasing number of “umbrella” protocols appearing in Early Phase Research.
“The UK remains the best place to undertake Phase 1 research” commented CEO Dr Mark Dale “and we are pleased to add a new commercial unit to the list of those accredited by the MHRA. Our expert team led by Charlotte Chadwick and Peter Dewland has a relentless commitment to continually improving safety and quality and our MHRA Accreditation provides volunteers and sponsors with additional reassurance of the high standards at MAC in performing clinical studies.”